Predicting the Response of Patients With Rheumatoid Arthritis to Treatment With Genetically Engineered Biological Drugs and Janus (JAK) Kinase Inhibitors

NCT06177405 · clinicaltrials.gov ↗

COMPLETED

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

DRUG: genetically engineered biological drugs, Janus-kinase inhibitors, tumor necrosis factor inhibitors

Sponsor

Institute of Biomedical Chemistry, Russia

Collaborators

[object Object]